339-P: Glycemic Variability Assessed by CGM Relates to Hypoglycemia across the Lifespan in Type 1 Diabetes (T1D)

Abstract

Aim: CGM can predict and reduce hypoglycemia in persons with T1D by providing real-time (RT) glucose levels and trend arrows. Using CGM data, one can assess glycemic variability with coefficient of variation for glucose (CV, glucose SD/mean x 100%). Current guidelines target a CV ≤36, given its association with reduced occurrence of hypoglycemia. Methods: As glycemic levels fluctuate across the lifespan, we aimed to evaluate associations between CV and hypoglycemia (time below range [TBR] Results: Across all studies, higher CV was associated with more TBR (all p 36 vs. CV≤36, TBR was higher in all 3 cohorts (p Summary: CGM use helped to reduce CV and TBR over time. These 3 studies affirm that glycemic variability (CV) relates to hypoglycemia across the lifespan in T1D. Disclosure B. A. Cooper: Speaker’s Bureau; Self; Regeneron Pharmaceuticals Inc. K. Miller: Other Relationship; Self; Dexcom, Inc., Tandem Diabetes Care, Research Support; Self; JDRF, Leona M. and Harry B. Helmsley Charitable Trust. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc. Funding National Institute of Diabetes and Digestive and Kidney Diseases (P30DK036836); The Leona M. and Harry B. Helmsley Charitable Trust